title: A multicenter, double-blind, trimethoprim-sulfamethoxazole controlled study of enoxacin in the treatment of patients with complicated urinary tract infections.
abstract: In a double-blind, randomized, controlled trial, 249 patients with complicated urinary tract infections received either 400 mg. enoxacin or 160 mg. trimethoprim plus 800 mg. sulfamethoxazole orally every 12 hours for 14 days. The clinical outcome at the end of treatment revealed that all 89 evaluable patients (100 per cent) in the enoxacin group and 88 of 90 (98 per cent) in the trimethoprim-sulfamethoxazole group had satisfactory clinical responses (cure or improvement). Bacteriological effectiveness was measured cumulatively based on responses during and at the end of treatment, and 7 days later at followup. Satisfactory bacteriological responses (eradication or superinfection at all evaluations throughout the study) were achieved in significantly more (p equals 0.03) patients treated with enoxacin (93 per cent) than in those treated with trimethoprim-sulfamethoxazole (83 per cent). Both study medications were well tolerated. These results indicate that oral enoxacin was more effective clinically and bacteriologically (the latter statistically so) than trimethoprim-sulfamethoxazole when given as empiric therapy in the treatment of complicated urinary tract infections.
authors.affiliation: Warner-Lambert/Parke-Davis Pharmaceutical Research Division, Ann Arbor, Michigan 48105.
authors.forename: C E
authors.initials: CE
authors.lastname: Cox
authors.forename: D M
authors.initials: DM
authors.lastname: Drylie
authors.forename: I
authors.initials: I
authors.lastname: Klimberg
authors.forename: S J
authors.initials: SJ
authors.lastname: Childs
authors.forename: J D
authors.initials: JD
authors.lastname: Wegenke
authors.forename: G H
authors.initials: GH
authors.lastname: Malek
authors.forename: L H
authors.initials: LH
authors.lastname: Harrison
authors.forename: D L
authors.initials: DL
authors.lastname: McCullough
authors.forename: S M
authors.initials: SM
authors.lastname: Finegold
authors.forename: W L
authors.initials: WL
authors.lastname: George
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D015365:Enoxacin / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011552:Pseudomonas Infections / Q000188:drug therapy; D011897:Random Allocation; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D015365:Enoxacin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole